Mustang Bio Announces Closing of $8 Million Public Offering

Core Viewpoint - Mustang Bio, Inc. has successfully closed a public offering, raising approximately $8 million through the issuance of 2,657,807 shares of common stock and accompanying warrants, aimed at funding working capital and corporate purposes [1][2]. Group 1: Offering Details - The public offering included 2,657,807 shares of common stock and Series C-1 and C-2 warrants, each with an exercise price of $3.01 per share [1]. - The Series C-1 warrants will expire five years from stockholder approval, while the Series C-2 warrants will expire in twenty-four months [1]. - The gross proceeds from the offering, before fees and expenses, were approximately $8 million [2]. Group 2: Use of Proceeds - Mustang intends to utilize the net proceeds from the offering for working capital and general corporate purposes [2]. Group 3: Company Overview - Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for difficult-to-treat cancers [5]. - The company aims to acquire rights to innovative technologies and has partnered with leading medical institutions to advance CAR-T therapies [5]. - Mustang Bio's common stock is registered under the Securities Exchange Act of 1934, and it files periodic reports with the SEC [5].